Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
TScan Therapeutics is a clinical-stage biotechnology company developing T-cell receptor (TCR) engineered T-cell therapies for solid tumors, focusing on targeting tumor-associated antigens. The company's lead programs include TSC-100 and TSC-101 targeting various solid tumor indications, with clinical trials ongoing as of early 2026. With minimal revenue, a $100M market cap, and substantial cash burn, the stock trades as a binary clinical-stage biotech bet on trial readouts and regulatory milestones.
TScan operates as a pre-revenue clinical-stage biotech, funding operations through equity raises and potential partnership agreements. The business model depends on advancing TCR-engineered T-cell therapy candidates through Phase 1/2 trials, demonstrating clinical efficacy and safety, then either partnering with larger pharma companies for commercialization (receiving upfront payments, milestones, and royalties) or building internal commercial capabilities. Value creation hinges on positive clinical trial data, regulatory approvals, and eventual market penetration in oncology indications with limited treatment options. The company has no pricing power until commercial launch, and competitive advantage depends on proprietary TCR discovery platform and clinical differentiation.
Clinical trial data readouts for TSC-100 and TSC-101 programs - objective response rates, duration of response, safety profiles
Regulatory milestone achievements - IND clearances for new programs, FDA feedback on trial designs, potential breakthrough therapy designations
Partnership announcements with larger pharmaceutical companies - upfront payments, validation of platform technology
Cash runway updates and equity financing announcements - dilution concerns versus runway extension
Competitive clinical data from other TCR-T or CAR-T companies targeting similar solid tumor indications
Clinical trial failure risk - solid tumor TCR-T therapies face significant efficacy and safety hurdles including tumor microenvironment penetration, antigen escape, and cytokine release syndrome; historical Phase 2 failure rates exceed 70% in oncology
Regulatory pathway uncertainty - FDA requirements for cell therapy approvals continue evolving, with potential for additional safety monitoring, manufacturing controls, or efficacy endpoints that could delay timelines or increase development costs
Manufacturing scalability challenges - autologous T-cell therapies require complex patient-specific manufacturing with high costs ($300K-500K per treatment) and logistical complexity that limits commercial viability
Intense competition from well-funded CAR-T and TCR-T programs at Adaptimmune, Immatics, Gilead, Bristol Myers Squibb targeting overlapping solid tumor indications with more advanced clinical programs
Platform technology risk - if competitors demonstrate superior TCR discovery methods, better manufacturing processes, or more effective T-cell engineering approaches, TScan's pipeline could become obsolete before commercialization
Cash runway depletion - with $100M market cap, negative $100M annual operating cash flow, and no revenue, the company faces near-term financing needs likely within 12-18 months, creating significant dilution risk
Equity financing dependency - 0.9x price/book ratio indicates market values company near liquidation value; future capital raises at depressed valuations could result in 50%+ dilution to existing shareholders
Going concern risk - if clinical data disappoints or financing markets remain closed, the company may lack resources to complete ongoing trials or advance pipeline, potentially forcing asset sales or wind-down
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as R&D spending is driven by clinical milestones rather than economic cycles. However, financing conditions and investor risk appetite for speculative biotech stocks are highly cyclical, affecting ability to raise capital and stock valuation multiples during economic downturns.
Rising interest rates negatively impact TScan through multiple channels: (1) higher discount rates compress NPV of distant future cash flows, disproportionately affecting pre-revenue companies with 5-10 year commercialization timelines, (2) risk-free rate competition makes speculative biotech investments less attractive relative to bonds, (3) tighter financial conditions reduce availability of growth capital and increase dilution risk in future equity raises. With 6.44x current ratio and minimal debt (0.66x D/E), direct interest expense impact is limited, but equity valuation multiples contract significantly in rising rate environments.
Minimal direct credit exposure given limited debt usage and pre-revenue status. However, broader credit market conditions affect biotech sector financing availability - tighter credit spreads and risk-off sentiment reduce venture capital and public market appetite for clinical-stage biotech equity, potentially forcing financing at unfavorable terms or delaying programs due to capital constraints.
growth - Attracts high-risk tolerance biotech specialists and momentum traders seeking binary clinical catalyst events with potential for multi-bagger returns on positive data. Not suitable for value or income investors given pre-revenue status, negative cash flows, and lack of dividends. Typical holders include specialized healthcare hedge funds, biotech-focused venture investors, and retail speculators willing to accept 50-80% downside risk for 200-500% upside potential on successful clinical development.
high - Clinical-stage biotech stocks exhibit extreme volatility with 30-50% single-day moves common around data readouts. With $100M market cap and limited institutional ownership, TScan experiences low liquidity and wide bid-ask spreads. Historical beta likely exceeds 2.0x relative to biotech indices, with 52-week decline of 50.7% reflecting sector-wide derating and company-specific clinical or financing concerns.